United Therapeutics Corporation UTHR
Composite 65/100; the shares have moved about 33% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 42/100 — a slight mark against it.
Balance-sheet strength ranks 93/100 — a strong point in its favour. Quality ranks 79/100 — a strong point in its favour. Growth ranks 59/100 — a slight point in its favour.
Valuation ranks 42/100 — a slight mark against it. Momentum ranks 45/100 — a slight mark against it.
What the company does United Therapeutics (UTHR) develops and sells therapies for pulmonary arterial hypertension (PAH), neuroblastoma, and preclinical organ xenografts. Its marketed products include Tyvaso, Remodulin, Orenitram, and Adcirca, with pipeline candidates like Ralinepag and RemunityPRO Pump targeting PAH and fibrosis.
Key financials UTHR reports strong profitability with gross margins of 86.6%, operating margins of 41.7%, and net margins of 40.6%. ROE is 20.3%, ROA 12.6%, and ROCE 26.6%. Revenue declined -1.6% YoY, while EPS fell -12.2%. The balance sheet is robust with a current ratio of 4.79 and interest coverage of 99.09.
Stock health Momentum shows mixed signals: -7.92% over 3 months but +12.52% over 6 months and +76.71% over 12 months. RSI(14) is 41.40, indicating neither overbought nor oversold conditions. Sideravia scores Quality at 79.7 and Strength at 96.2, reflecting strong fundamentals.
Price vs fair value The stock trades at a **discount** of 3.50% to our fair-value estimate (544.19) and a **discount** of 26.13% to the analyst 12-month target (663.23). - CEO insider sale of $5M may weigh on sentiment (Motley Fool) - Broader biotech volatility linked to AI-insider selling (Bloomberg) - Analyst count of 13.0 supports long-term upside potential
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.